Table 1.
Doses and schedules of current regimens for metastatic UC in Japan
| Drug | Dose and schedule | Duration of cycles (days) |
|---|---|---|
| Pembrolizumab | ||
| Pembrolizumab | 200 mg, day 1 | 21 |
| Gemcitabine/Cisplatin (GC) regimen | ||
| Gemcitabine | 1 g/m2, days 1, 8, 15 | 28 |
| Cisplatin | 70 mg/m2, day 2 | |
| MVAC regimen | ||
| Methotrexate | 30 mg/m2, days 1, 15, 22 | 28 |
| Vinblastine | 3 mg/m2, days 2, 15, 22 | |
| Adriamycin | 30 mg/m2, day 2 | |
| Cisplatin | 70 mg/m2, day 2 | |
| Gemcitabine/Carboplatin (GCa) regimen | ||
| Gemcitabine | 1 g/m2, days 1, 8 | 21 |
| Carboplatin | AUC5, day 2 | |
| Paclitaxel/cisplatin/gemcitabin (PCG) regimen | ||
| Paclitaxel | 80 mg/m2, days 1, 8 | 21 |
| Cisplatin | 50–70 mg/m2, days 2 | |
| Gemcitabine | 1 g/m2, days 1, 8 | |
| Gemcitabine and paclitaxel (GP) regimen | ||
| Gemcitabine | 1 g/m2, days 1, 8 | 21 |
| Paclitaxel | 175 mg, day 1 | |
AUC area under the concentration curve